<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8FB318B6-3327-4F02-A33D-EFA641BA2B88"><gtr:id>8FB318B6-3327-4F02-A33D-EFA641BA2B88</gtr:id><gtr:firstName>Roger John</gtr:firstName><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/165691B8-AFD5-48DE-89CC-512CE600302C"><gtr:id>165691B8-AFD5-48DE-89CC-512CE600302C</gtr:id><gtr:firstName>Herbie</gtr:firstName><gtr:surname>Newell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0BAA93B0-93DD-42C5-B63A-065A67C1F6CD"><gtr:id>0BAA93B0-93DD-42C5-B63A-065A67C1F6CD</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Carroll</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F86B7E0D-6250-4C35-A5F0-FC7E436B384F"><gtr:id>F86B7E0D-6250-4C35-A5F0-FC7E436B384F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Matthew</gtr:otherNames><gtr:surname>Blamire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FE000657%2F1"><gtr:id>DBE55344-ABBD-4047-9DE8-4785C4840E95</gtr:id><gtr:title>FLIC - Functional Ligands for Imaging in Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/E000657/1</gtr:grantReference><gtr:abstractText>Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are two essential imaging methods whose clinical application in cancer research is well established. Recent advances in clinical instrumentation have resulted in equipment with improved resolution and sensitivity. However, current contrast or imaging agents for use in MRI and PET are not as effective for the 21st century instrumentation now being deployed. The design, synthesis and validation of improved, new functional imaging probes is urgently needed. To develop such probes for cancer a multidisciplinary team is required with expertise in synthetic chemistry and radiochemistry, pre-clinical and clinical imaging sciences, and cancer drug development, working in harmony with the needs and aspirations of cancer biology. No single grouping in the UK can currently offer this range of expertise, and therefore to make progress in this important area the formation of a multi-centre collaborative grouping is essential. The proposed FLIC platform grant will establish a collaborative team with strengths in chemistry, cancer imaging and drug development, and in so doing create a chemistry-life science interface that will address a key need in personalised medicine, producing new chemical entities with genuine utility for healthcare providers and amenable to commercial exploitation.</gtr:abstractText><gtr:fund><gtr:end>2010-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2006-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>418330</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Univeristy of Durham</gtr:description><gtr:id>9ABCE315-F8A9-422C-878C-4B351E30426D</gtr:id><gtr:impact>See publications</gtr:impact><gtr:outcomeId>VAM1yaCiqYm-1</gtr:outcomeId><gtr:partnerContribution>Joint grantee</gtr:partnerContribution><gtr:piContribution>Joint grantee on Programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interaction with pharma and biotech</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>663B5526-B115-470D-BC93-B29EA0071938</gtr:id><gtr:impact>Contacts with numerous pharma and boitech employees

Clinical trials on novel agents with imaging endpoints brought to Newcastle</gtr:impact><gtr:outcomeId>bhNTzFWxQzK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C29821/A10348</gtr:fundingRef><gtr:id>1499369D-B15E-4AC6-A000-1FBF6E93982D</gtr:id><gtr:outcomeId>r-7905322944.65724706a7a18e</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CF8069A0-718A-424A-AD23-BDAB04EE7796</gtr:id><gtr:title>19F-lanthanide complexes with increased sensitivity for 19F-MRI: optimization of the MR acquisition.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>DKyM5YPoan6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B186C6EF-F46D-4E65-92BC-34DF88222CC3</gtr:id><gtr:title>Design principles and theory of paramagnetic fluorine-labelled lanthanide complexes as probes for (19)F magnetic resonance: a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>fGN7HFRf1dD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC71BB71-B679-421C-9ABA-18DBD9FFDE0B</gtr:id><gtr:title>THE FIRST SYNTHESIS OF ETHYL 3-[F-18]FLUOROBENZOATE USING [F-18]FLUORIDE</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>LhLhjNLdCjy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE3DDE6-C0DA-41DC-B9E5-CC762500B2C2</gtr:id><gtr:title>Strategies to enhance signal intensity with paramagnetic fluorine-labelled lanthanide complexes as probes for 19F magnetic resonance.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/470904b70b5da14c4b918058a2920d6b"><gtr:id>470904b70b5da14c4b918058a2920d6b</gtr:id><gtr:otherNames>Chalmers KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>doi_53d02d02d1f58ee5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA9863C-C393-4CA3-9405-5FBE647E45B1</gtr:id><gtr:title>The first preparation of all regioisomers of ethyl [(18)f]fluorobenzoates</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>NHJuvf1fCq7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A93464E-4961-4C25-8C91-F4DC97F5ED27</gtr:id><gtr:title>THE FIRST SINGLE-STEP-SINGLE-POST SYNTHESIS OF 4-[F-18]SFB</gtr:title><gtr:parentPublicationTitle>JOURNAL OF LABELLED COMPOUNDS &amp; RADIOPHARMACEUTICALS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6375fb0d4579218eafc36e32d39c1574"><gtr:id>6375fb0d4579218eafc36e32d39c1574</gtr:id><gtr:otherNames>Yan Ran</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>HPTJ1ezLTw2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/E000657/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>